Altimmune (NASDAQ:ALT) Earns Buy Rating from HC Wainwright

Altimmune (NASDAQ:ALT)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $12.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 206.12% from the company’s previous close.

Several other brokerages have also recently issued reports on ALT. Wall Street Zen raised shares of Altimmune from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. William Blair reiterated a “market perform” rating on shares of Altimmune in a research note on Friday, June 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research note on Wednesday. JMP Securities lowered their target price on shares of Altimmune from $25.00 to $15.00 and set a “market outperform” rating on the stock in a research report on Thursday, July 10th. Finally, B. Riley lowered their price objective on shares of Altimmune from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 13th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $17.40.

Altimmune Trading Down 2.0%

NASDAQ ALT opened at $3.92 on Friday. The firm’s 50-day moving average is $3.72 and its two-hundred day moving average is $4.61. Altimmune has a 12 month low of $2.90 and a 12 month high of $11.16. The company has a debt-to-equity ratio of 0.09, a current ratio of 20.44 and a quick ratio of 20.44. The stock has a market capitalization of $345.98 million, a P/E ratio of -3.32 and a beta of 0.07.

Altimmune (NASDAQ:ALT) last posted its earnings results on Tuesday, August 12th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.05. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. On average, sell-side analysts anticipate that Altimmune will post -1.35 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ALT. GAMMA Investing LLC lifted its holdings in shares of Altimmune by 214.2% during the 1st quarter. GAMMA Investing LLC now owns 6,745 shares of the company’s stock worth $34,000 after acquiring an additional 4,598 shares during the period. BNP Paribas Financial Markets increased its position in Altimmune by 108.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after purchasing an additional 5,253 shares in the last quarter. Kingswood Wealth Advisors LLC acquired a new stake in Altimmune during the 2nd quarter worth approximately $40,000. Prudential Financial Inc. acquired a new stake in Altimmune during the 2nd quarter worth approximately $43,000. Finally, Headland Capital LLC acquired a new stake in Altimmune during the 1st quarter worth approximately $50,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.